Compare Novartis AG (NVS) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs T Rowe Price Group Inc — how do they compare? Novartis AG trades at $143.75 (market cap $268.57B), while T Rowe Price Group Inc trades at $105.26 (market cap $22.23B). The key difference: Novartis AG is far larger — about 12.1× T Rowe Price Group Inc's market cap, and T Rowe Price Group Inc pays the higher dividend (4.99%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and T Rowe Price Group Inc for 115 Days on average.
| NVS | TROW | |
|---|---|---|
Market Cap | $268.57B | $22.23B |
Volume | 1,532,573 | 2,834,949 |
Sector | Health | Financials |
52-Week High | $168.62 | $121.68 |
52-Week Low | $121.80 | $86.19 |
Typical Hold Time | 82 Days | 115 Days |
Enterprise Value | $309.89B | $19.43B |
Dividend Yield | 3.31% | 4.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.75, up 0.33% on the day, near the consensus price target of $146.00. Recent earnings show mixed quarterly beats and a miss in Q1 2026, with revenue growth to $56.67B in 2025 and a net income margin of 24.67%. Technical indicators signal a bearish trend, while analyst sentiment is mixed with 24% buy ratings. The company recently announced a $7.8B licensing deal with China's Abogen for mRNA therapy, but faces scrutiny over clinical setbacks and M&A strategy.
The outlook for NVS hinges on execution of its pipeline and deal integration amid investor caution. Opportunities include expansion into autoimmune treatments and solid profitability, but risks involve trial failures, regulatory probes, and debt levels rising to 30.26% of assets. Wall Street remains neutral with a slight upside to the price target.
T. Rowe Price (TROW) trades at $105.16, up 1.05% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $7.31B revenue, 29.26% net margin, and attractive valuation at 10.46 P/E. Recent earnings show two beats out of three quarters, while assets under management reached $1.90T in August 2026 despite net outflows.
TROW presents a compelling value opportunity with solid dividend growth and reasonable valuation, though technical weakness and analyst caution warrant attention. The stock's 40-year dividend growth history and expanding ETF offerings through F/m Investments acquisition provide stability, while market volatility and fee pressure remain key risks for the asset management business.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
